First report of whole-genome analysis of an extensively drug-resistant *Mycobacterium tuberculosis* clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda

Jupiter Marina Kabahita¹, Joel Kabugo¹, Francis Kakooza³, Isa Adam¹, Ocung Guido¹, Henry Byabajungu¹, Joanith Namutebi¹, Maria Magdalene Namaganda⁴, Pius Lutaaya¹, James Otim⁶, Fredrick Elishama Kakembo⁵, Stephen Kanyerezi⁷, Patricia Nabisubi⁵, Ivan Sserwadda⁴, George William Kasule¹, Hasfah Nakato¹, Kenneth Musisi¹, Denis Oola¹, Moses L. Joloba¹,⁴ and Gerald Mboowa²,³*

**Abstract**

**Background:** Uganda remains one of the countries with the highest burden of TB/HIV. Drug-resistant TB remains a substantial challenge to TB control globally and requires new strategic effective control approaches. Drug resistance usually develops due to inadequate management of TB patients including improper treatment regimens and failure to complete the treatment course which may be due to an unstable supply or a lack of access to treatment, as well as patient noncompliance.

**Methods:** Two sputa samples were collected from Xpert MTB/RIF® assay-diagnosed multi-drug resistant tuberculosis (MDR-TB) patient at Lira regional referral hospital in northern Uganda between 2020 and 2021 for comprehensive routine mycobacterial species identification and drug susceptibility testing using culture-based methods. Detection of drug resistance-conferring genes was subsequently performed using whole-genome sequencing with Illumina MiSeq platform at the TB Supranational Reference Laboratory in Uganda.

**Results:** In both isolates, extensively drug-resistant TB (XDR-TB) was identified including resistance to Isoniazid (katG p.Ser315Thr), Rifampicin (rpoB p.Ser450Leu), Moxifloxacin (gyrA p.Asp94Gly), Bedaquiline (Rv0678 Glu49fs), Clofazimine (Rv0678 Glu49fs), Linezolid (rplC Cys154Arg), and Ethionamide (ethA c.477del). Further analysis of these two high quality genomes revealed that this 32 years-old patient was infected with the Latin American Mediterranean TB strain (LAM).

**Conclusions:** This is the first identification of extensively drug-resistant *Mycobacterium tuberculosis* clinical isolates with bedaquiline, linezolid and clofazimine resistance from Uganda. These acquired resistances were because of non-adherence as seen in the patient’s clinical history. Our study also strongly highlights the importance of combating...
Background

Uganda is a high burden country for both HIV and Tuberculosis (TB) [1]. Worldwide, drug resistant forms of TB undermine the efforts to curb TB disease. An estimated 1500 people fell ill with drug resistant TB (DR-TB) in 2018 with only 34% of these being notified to the Uganda National TB Program with treatment success rate for DR-TB of only 64% [2]. Between 2014 and 2018, the incidence of rifampicin-resistant tuberculosis (RR-TB) increased especially among newly diagnosed TB patients with males being more affected by RR-TB than females [3]. A number of challenges such as patient adherence, long duration of treatment and late diagnosis have also been linked to treatment failure in TB therapy [4]. Particularly, longer regimens involved in the treatment of DR-TB can potentially explain the higher non-adherence and treatment defaulting seen in these patients [5].

Multi-Drug Resistant TB (MDR-TB) is TB that is resistant to atleast Rifampicin and Isoniazid. These are the two most effective anti-TB drugs and resistance to them warrants the use of second line anti-TB drugs that are less effective, more costly, and more toxic [6]. Previously, extensively drug resistant TB (XDR-TB) was defined as MDR-TB that had additional resistance to any fluoroquinolones and any one of the second line injectables (Amikacin, Capreomycin and Kanamycin). This definition has now been redefined to reflect changes in policy and treatment guidelines as there has been a declining priority in the use of the second line injectables and increased importance of drugs like Bedaquiline and Linezolid. XDR-TB currently, is defined as MDR-TB that is resistant to a fluoroquinolone and either Bedaquiline or Linezolid or both [6].

Bedaquiline, Linezolid and Clofazimine have over the years gained importance in treatment of drug resistant TB, Bedaquiline and Linezolid are now classified as Group A second line drugs while Clofazimine is classified as a Group B [6]. Resistance to these drugs is still rare but has been reported elsewhere [7–9] including TB drug naive patients [10–12]. Therefore, monitoring resistance to these drugs is of paramount importance given they are now a part of important regimens to treat resistant TB.

Cross resistance to Bedaquiline and Clofazimine has been attributed to mutations occurring in genes \textit{Rv0678}, \textit{mmpS5-mmpL5}, \textit{Rv1979c}, and \textit{pepQ}. In addition to these genes, mutations in the \textit{atpE} gene which is the primary target for Bedaquiline cause a much higher level of resistance to Bedaquiline, these mutations are not known to confer cross-resistance to Clofazimine [9, 10, 13, 14]. Resistance to Linezolid has been attributed to mutations occurring in genes \textit{rplC} and \textit{rrl} [7].

In this report, we present the first identified XDR clinical isolate of \textit{Mycobacterium tuberculosis} (M. tb) that had confirmed phenotypic resistance to Bedaquiline, Linezolid and Clofazimine. This resistance was displayed by two sputa samples from the same patient collected at different time points. To identify the possible genetic causes of resistance in these samples, Whole-genome sequencing (WGS) of both isolates was carried out.

Case presentation

A 32-year-old male patient with HIV negative serostatus was admitted at Lira Regional referral hospital in Northern Uganda as a failure on the first line regimen (Rifampicin, Isoniazid, Ethambutol and Pyrazinamide). At admission, the patient had a baseline weight of 50 kg and Chest X-ray conducted showed heterogeneous opacities bilaterally, with obliterated costophrenic angles bilaterally. The patient was confirmed Rifampicin Resistant (RR) by Xpert MTB/RIF assay on 30/7/2017 from a lower peripheral facility with cycle threshold (ct) values of 10. A sputum sample was first collected from the patient and referred to the National Tuberculosis Reference Lab (NTRL) for culture and drug susceptibility testing. The patient was initiated on DR-TB treatment regimen composed of Kanamycin (800 cc), Levofloxacin(1000 mg), Ethionamide (750 mg), Cycloserine (500 mg), and Pyrazinamide (1200 mg) on 31/7/2017. Results from the patient's initial sample were 3+ for acid-fast bacillus (AFB) smear microscopy, \textit{M. tb} Colony growth of 3+ on Lowenstein Jensen media (LJ) and confirmed positive for \textit{M. tb} on Mycobacteria Growth Indicator Tube (MGIT) liquid culture system with a time to detection (TTD) of 4 days and 12 h. Routine phenotypic drug susceptibility (p-DST) testing results for this baseline sample collected on 31/08/2017 confirmed resistance to both Rifampicin and Isoniazid and susceptibility to Fluoroquinolones, Ethambutol and the second-line injectables. Month one follow-up results were negative for acid fast bacilli on smear microscopy but had \textit{M. tb} colony growth of 1+ on
LJ and positive for *M. tb* on MGIT culture with a TTD of 19 days and 4 h. Follow-up at month two had negative results for both smear microscopy and mycobacterial culture. Patient was declared lost to follow-up (LTFU) on 12/12/2017.

The patient was re-registered on 12/05/2018 and initiated on the same DR-TB treatment regimen 6 km Lfx Cs Eto Z /14 Lfx Cs Eto Z. Results from the sample referred to the NTRL at re-registration were 3+ for AFB smear microscopy, colony growth of 3+ on LJ culture media and confirmed positive on MGIT culture with a TTD of 5 days and 7 h. The patient's mycobacterial culture converted at month four on 08/09/2018 but later reverted at month six (07/11/2018). The results for month six reversal showed negative AFB smear microscopy, colony growth of 2+ on LJ, confirmed positive MGIT culture with a TTD of 10 days and 11 h as well as resistance to fluoroquinolones both p-DST and Line probe assay. p-DST also revealed resistance to Streptomycin at this point. p-DST done on 08/05/2019 for Clofazimine and Bedaquiline for follow-up at month twelve showed susceptibility to both drugs but still resistant to Streptomycin, fluoroquinolones, Rifampicin, and Isoniazid. The patient was declared a treatment failure on 03/06/2019.

The patient was re-registered on 29/07/2019 on a regimen containing 24 Bdq Dlm Lzd Eto Cs Z as recommended by the Ugandan National MDR panel, the culture converted at month 5 but reverted at month 6, p-DST for follow-up month 7 still showed sensitivity to Bedaquiline, Clofazimine and Linezolid. The patient was LTFU after month 10 since his TB treatment got interrupted for more than two consecutive months. He was later re-registered on 2/6/2020 on the regimen 12 Bdq Lzd Dlm Cz Eto Z. Follow-up p-DST at month two (M2) and three (M3) on this new regimen showed resistance to Bedaquiline, Clofazimine and Linezolid. The patient was declared LTFU 02/02/2021 and his whereabouts remain unknown to date.

**Materials and methods**

**Phenotypic drug susceptibility testing and isolate identification**

All laboratory processes in this study were carried out at the NTRL-Uganda/World Health Organization (WHO) Supra-National Tuberculosis Reference laboratory (SRL). Routinely all MDR-TB patients in Uganda are followed-up every month for 24 months with samples being collected at their respective treatment centers and referred to NTRL-Uganda for comprehensive laboratory analysis. In this case report, we describe two patient samples (M2 and M3) collected at Lira regional referral hospital as part of TB patient care. Each sample received was processed using 6.0% sodium hydroxide (NaOH) in the N-acetyl-L-cysteine-sodium hydroxide (NALC-NaOH) mixture before performing Auramine-O smear microscopy, mycobacterial culture, and drug susceptibility on both MGIT and LJ methods (Additional file 1 and 2 respectively), all these are carried out as part of TB patient care. On both LJ and the BACTEC MGIT 960 system, samples were tested for resistance to both first and second anti-TB drugs using WHO-recommended critical concentrations [15] and NTRL-Uganda in-house protocols as described in Additional file 1 and 2. Drugs that were tested included Isoniazid, Ethambutol and Rifampicin at critical concentrations. Second-line anti-TB drugs Levofloxacin, Moxifloxacin and Amikacin were tested on both MGIT and LJ methods. In addition to MGIT drugs, we also tested other drugs such as Linezolid, Bedaquiline, Clofazimine and Delamanid. Quality control using *M. tb* strains H37RV, MX and KA was done to ensure reliability of results obtained. Control strains M. tuberculosis, Clofazimine and Delamanid resistance recorded in clinical isolates (Additional file 3).

**Sub-culture and DNA extraction**

The isolates were sub-cultured on selective Middlebrook 7H11 agar (Becton and Dickson, USA) and incubated at 37 °C in a CO₂ incubator (Panasonic, Osaka, Japan) monitored weekly for mycobacterial growth. During the 4th week, sufficient colonies were observed, and these were harvested into a 15 ml falcon tube with 1 ml of sterile water. Following a 30 min heat inactivation at 85 °C, high quality genomic DNA was extracted using an in-house cetyl trimethylammonium bromide (CTAB) method as previously described [16]. Quality of the extracted DNA was assessed using the 4150 TapeStation system (Agilent, USA) with the Agilent Genomic DNA Screen Tape and reagents. Purity of the DNA was assessed using the Nano-Drop 2000c (Thermo-Fisher Scientific).

**Library preparation and whole-genome sequencing**

Genomic libraries were prepared using the Illumina Nextera XT library preparation kit following manufacturer's instruction [17]. Quality of the prepared genomic libraries was assessed with the Agilent 4150 TapeStation system using the D1000 High sensitivity Screen Tape and reagents. Genomic libraries were sequenced on the MiSeq platform (Illumina, San Diego, CA, USA) using the Illumina MiSeq V3 cartridge.
Bioinformatics analysis

Drug resistance determination and variant calling

Quality of reads was assessed using FastQC v0.11.8 [18] and MultiQC v1.0 [19]. TB-Profiler v3.0.4 [20] pipeline was run to identify resistance to the different anti-TB drugs. For potential novel mutations conferring resistance to the newly approved anti-TB drugs, the pipeline described next was used. Genomic reads were aligned to the M. tb H37Rv NC_000962.3 reference genome using BWA v0.7.17-r1188 [21] with the mem algorithm generating SAM files which were converted into BAM files using SAMtools v1.9 [22]. These SAM files were subsequently sorted and indexed using the same version of SAMtools. Variant calling was done using FreeBayes v1.3.2 [23], a variant was only called if the read depth at that position was greater than 10 and the variant had a Phred quality score of 15 or higher.

Variants were annotated using SnpEff v4.3 [24]. Custom bash scripts were used to identify potential drug resistance-conferring mutations in the genes Rv0678, mmpL5, mmpS5, pepQ, and Rv1979c for both Bedaquiline and Clofazimine resistance. In addition to these genes, the atpE gene was included for Bedaquiline resistance. Other genes including fbiA, fbiB, fbiC, Rv2983, fgd1, and ddn were interrogated for potential resistance-conferring gene variants to Delamanid and Pretomanid while for Linezolid resistance, the genes rplC and rrl were interrogated.

Phylogenetic analysis

Phylogenetic analysis of the samples was done alongside 169 M. tb samples from Uganda under the Sequence Read Archive experiment numbers PRJEB10577, PRJNA354716 and PRJNA481638 (Fig. 1). The samples were called for variants using snippy v4.6.0 [25]. Twenty-four of the samples were excluded from the downstream analysis as these flagged a “[markdup] error.

To build a high-resolution phylogeny, a snp core alignment was first performed using snippy core [25]. Gubbins v2.4.1 [26] was used to produce an alignment file with recombinant sites masked. Snp-sites v2.5.1 [27] was then used to clean the alignment and only retain sites with exclusively ACGT. Using Fasttree v2.1.10 [28], a tree for a nucleotide alignment with the GTR + CAT substitution
model was inferred. To visualize the tree, iTOL v.6.3 [29] was used to display and manipulate the phylogenetic tree.

**Results**

**Resistance associated mutations to the different anti-TB drugs**

Our analysis showed that there was agreement between MGIT and WGS drug resistance results. Analysis of both sequences using TB-Profiler confirmed resistance conferring mutations \(rpoB\) \(p.Ser450Leu\), \(katG\) \(p.Ser315Thr\), \(gyrA\) \(p.Asp94Gly\), \(rplC\) \(p.Cys154Arg\) known to cause resistance to drugs Rifampicin, Isoniazid, fluoroquinolones, and Linezolid respectively (Table 1).

**Other identified mutations in the genes conferring resistance to the bedaquiline, clofazimine, linezolid, and delamanid**

TB-Profiler was only able to confirm genotypic resistance to Linezolid and other drugs, but because the isolates were displaying phenotypic resistance to Bedaquiline and Clofazimine, we decided to interrogate the genes that have so far been implicated in resistance to both drugs for potential novel resistance conferring mutations. Our analysis identified several mutations in \(mmpL5\), \(pepQ\), \(Rv0678\), and \(Rv1979c\) (Table 2). \(Rv0678\) frame shift p.Glu49fs was confirmed to confer resistance to Bedaquiline and cross-resistance to Clofazimine [14], its occurrence in our two samples could potentially explain the observed phenotypic resistance to both drugs. No mutations were seen in the \(atpE\) gene for both samples.

The role of other mutations (Table 2) seen in these gene remains to be confirmed, only the mutation \(mmpL5\) p.Ile948Val has been confirmed not to be linked to drug resistance [1, 30]. We identified several mutations in genes implicated in resistance to Delamanid: \(fbiA\), \(fbiB\), \(fbiC\), \(fbi\), \(fgd1\), as well as \(ddn\). \(fbiC\) carried more mutations than other genes. Some of the mutations observed in one of the samples were at the same genomic position [(\(fbiC\) p.Leu672Val and p.Leu672Arg), \(ddn\) p.Glu35Lys, p.Glu35Gly)] which might be explained by the heterogeneous nature of the samples.

**Lineage analysis**

Lineage results from TB-Profiler showed that both samples belonged to MTBC lineage 4 sub-lineage LAM.

**Analysis of variants**

From the variant analysis, 696 variants were shared between M3 and M2. Eighty-four variants were exclusive to M3 and not M2. One variant only is present in M2 and not in M3. Isolate M3 accumulated more variants including complex variants (COMPLEX), deletions (DEL), insertions (INS), Multiple Nucleotide Polymorphism (MNP), single nucleotide polymorphisms (SNP), compared to M2 on average (Table 3).

---

**Table 1** Mutations identified conferring resistance to the different anti-TB drugs

| Drug        | Resistance profile | Gene mutation       |
|-------------|--------------------|---------------------|
| Rifampicin  | Resistant          | \(rpoB\) p.Ser450Leu |
| Isoniazid   | Resistant          | \(katG\) p.Ser315Thr |
| Fluroquinolones | Resistant  | \(gyrA\) p.Asp94Gly |
| Ethionamide | Resistant          | \(ethA\) c.477del    |
| Bedaquiline | Resistant          | \(Rv0678\) p.Glu49fs |
| Clofazimine | Resistant          | \(Rv0678\) p.Glu49fs |
| Linezolid   | Resistant          | \(rplC\) p.Cys154Arg |

**Table 2** Other potential resistance conferring mutations in the genes implicated in Bedaquiline, Clofazimine, Linezolid and Delamanid resistance

| Drug                  | Gene      | Other potential resistance conferring mutations                                      | Mutation type |
|-----------------------|-----------|-------------------------------------------------------------------------------------|---------------|
| Bedaquiline and       | \(mmpL5\) | p.Ile948Val, p.Gly131Arg, p.Thr352Pro                                              | Missense variants |
| Clofazimine           | \(Rv0678\) | p.Ala124Gly, p.Asp141Glu, p.Thr161Asn                                              | Missense variants |
|                       | \(Rv1979c\) | p.Ala128Ser, p.Pro349Ala                                                            | Missense variants |
|                       | \(pepQ\)   | p.Ala224Ser, p.Leu300Arg, p.Leu362Trp                                              | Missense variants |
| Linezolid             | \(rplC\)   | p.Gly153Glu, p.Ala153Asp, p.Thr156Pro                                              | Missense variants |
| Delamanid             | \(fgd1\)   | p.Ser38Arg, p.Thr92Pro, p.Phe102Cys, p.Gly199Ala, p.Glu213Asp                        | Missense variants |
|                       | \(fbiC\)   | p.Glu593Gly, p.Asp375Ala, p.Glu376Gly, p.Thr405Gly, p.Glu472Asp, p.Asp492Tyr, p.Glu503Gly, p.Glu535Arg, p.Leu672Val, p.Asp673Ala, p.Pro686Ala, p.Glu692Ala, p.Glu152* | Missense variants |
|                       | \(fbiA\)   | p.Val73Gly, p.Met319Arg                                                             | Nonsense mutation |
|                       | \(fbiB\)   | p.Ile18Val, p.Ser54Ala, p.Ala104Glu, p.Leu249Arg, p.Glu250Ala, p.Ser262Ala, p.Val263Gly, p.Glu35Lys, p.Glu35Gly, p.Asp108Glu | Missense variants |
|                       | \(ddn\)    | p.Glu35Lys, p.Glu35Gly, p.Asp108Glu                                                | Missense variants |
|                       | \(Rv2983\) | p.His159Pro                                                                         | Missense variants |
Discussion

Global control of tuberculosis continues to be impacted by the emergence and transmission of DR-TB which is associated with increased morbidity and mortality due to reduced treatment success. Current microbiological culture-based and molecular diagnostic tools such as Xpert MTB/Ultra and Line Probe Assay have limitations that could lead to delay of appropriate treatment initiation causing transmission of drug resistance. Furthermore, detection of DR-TB in Uganda relies on Xpert MTB/RIF and line probe assays (MTBDRplus and MTBDRsl). These assays are limited to detecting resistance to only first-line and second-line drugs but not to new anti-TB drugs in the treatment of MDR-TB. The Supranational TB Reference Laboratories (SRLs) should adopt next-generation sequencing (NGS) and easy to use bioinformatics pipelines for comprehensive rapid detection, monitoring and surveillance of M. tb drug resistance as well as identify their novel mechanisms of action.

One person with active untreated TB can spread the disease to as many as 15 other people in a year [31]. Our case was staying with his mother who also got infected with DR-TB however she was successfully treated and discharged in July 2021. About 15 percent of TB patients in Uganda abandon treatment and remain in the community settings [32]. The patient in this study exhibited very poor adherence to treatment behavior. He was declared LTFU twice on 12/12/2017 and 2/02/2021. This underscores the need for adequate clinical monitoring of these patients through modified directly observed treatment strategy (DOTS-Plus) which requires much effort from both the patients and health-care workers during treatment.

The quinolone resistance-determining region (QRDR) is comprised of conserved areas within gyrA and gyrB. Isolates harboring the gyrA Asp94Gly substitution have been reported to resist higher fluoroquinolones concentrations [33]. Similarly, mutations within the ethA structural genes are associated with relatively high levels of ethionamide (ETH) resistance [34]. The isolates in this report carried ethA c.477del.

Clofazimine has been repurposed for the treatment for MDR-TB [35]. But mutations in Rv0678 are a major mechanism of clofazimine-bedaquiline cross-resistance [36]. Rv0678 p.Glu49fs mutation identified in these isolates has also been reported by a study in KwaZulu-Natal, South Africa [14].

Another recent study has showed that 6.3% of MDR-TB patients without prior clofazimine or bedaquiline exposure harbored isolates with Rv0678 mutations, which raises concern that pre-existing resistance to these drugs may be associated with prior TB treatment [35]. The study recommended extensive surveillance and personalized testing for clofazimine and bedaquiline resistance, together with assessment of their clinical usage, especially among previously treated and MDR-TB patients [35]. The rplC p.Cys154Arg also identified in this study has been identified as a dominant mutation in linezolid-resistant M. tb strains elsewhere [37]. The patient in this study showed resistance to almost all new anti-TB drugs (bedaquiline, linezolid and clofazimine) that are currently suggested as priority drugs for MDR-TB treatment. Therefore, this study underscores the need to support TB treatment adherence. This study did not find any phenotypic or genomic pyrazinamide resistance. According to Uganda Programmatic Management of drug-resistant Tuberculosis (PMDT) guidelines, all newly diagnosed RR-TB/MDR-TB patients are started on a standard regimen—6 km-Lfx-Cs-Eto-Z/14Lfx-Cs-Eto-Z until their DSTs are available at which point, their treatment becomes individualized based on observed resistance and side effects profiles [38].

Conclusion and recommendation

We have documented a first report describing identification of extensively drug-resistant M. tb clinical isolates with Bedaquiline, Linezolid and Clofazimine resistance from Uganda through Whole-genome sequence analysis. These acquired resistances were because of non-adherence as seen in the patient’s clinical history. This finding has important implications for national TB control programmes in ensuring that patients devoutly adhere to their drugs and come back for monthly follow-up. We also recommend that MDR-TB patients with treatment interruptions or lost to follow-up need to obtain mycobacterial culture results for timely whole-genome sequencing. Our study also strongly highlights the importance of combating DR-TB in Africa through implementing next generation sequencing that can test resistance to all drugs while providing a faster turnaround time. This can facilitate timely clinical decisions in

**Table 3** Variants distribution in the two DR-TB M. tb clinical isolates (M2 was the first sample to be collected from the patient)

| Type             | M2   | M3   |
|------------------|------|------|
| Variant-complex  | 13   | 15   |
| Variant-DEL      | 29   | 36   |
| Variant-INS      | 25   | 36   |
| Variant-MNP      | 3    | 5    |
| Variant-SNP      | 627  | 688  |
| Total variants   | 697  | 780  |
managing MDR-TB patients with non-adherence or lost to follow-up.

Abbreviations
MTB: Mycobacterium tuberculosis; NTRL: National TB Reference Laboratory; WGS: Whole genome sequencing; TB: Tuberculosis; SRL: Supranational Reference Laboratory; XDR TB: Extensively drug resistant TB.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13756-022-01101-2.

Additional file1. Mycobacteria growth indicator tube (MGIT) drug susceptibility testing protocol.
Additional file2. Löwenstein-Jensen drug susceptibility testing protocol.
Additional file3. Detailed patient clinical and laboratory information.

Acknowledgements
A special thanks to the Nurturing Genomics and Bioinformatics Research Capacity in Africa (BreCA Award Number 1U2RTW010672-01) project for the bioinformatics training provided to JMK and MWN. We also thank Nile research support provided to JMK via the Infectious Diseases Institute, Makerere University. GM is supported by the Fogarty International Center of the National Institutes of Health under Award Number D43TW009771. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author contributions
JO collected the specimens, clinical data and clinical interpretation; JK, HB, GWK performed phenotypic drug susceptibility tests; IA, PL carried out molecular analysis; GM, JMK, JK, FK, OG, IA, PN prepared as well as wrote the draft manuscript; MLJ, DO, KM conceived the study. All authors read and approved the final manuscript.

Funding
We acknowledge the support rendered to the NTRL through the East, Central and Southern Africa Health Community (ECSA-HC) project that financed the procurement of the MiSeq sequencing platform, supporting equipment and reagents that were used in this study.

Availability of data and materials
The raw reads and/or assembly files from this study are publicly available at the SRA under the study BioProject ID: PRJNA749651 and at the Zenodo open-access repository https://doi.org/10.5281/zenodo.5136879.

Declarations
Ethics approval and consent to participate
The project was approved by the Makerere University School of Biomedical Sciences Research and Ethics Committee (SBSREC) on July 19, 2021.

Consent for publication
The participant has consented to the submission of the short report to the journal.

Competing interests
The authors declare that they have no competing interests.

Author details
1 National Tuberculosis Reference Laboratory/Supranational Reference Laboratory, Plot 106-1062 Butabika Road, Luzira, Uganda. 2 Africa Centres for Disease Control and Prevention, African Union Commission, Roosevelt Street, P.O. Box 3243, W21 K19 Addis Ababa, Ethiopia. 3 The Infectious Diseases Institute, College of Health Sciences, Makerere University, P.O. Box 22418, Kampala, Uganda. 4 Department of Immunology and Molecular Biology, College of Health Sciences, Makerere University, P.O. Box 77072, Kampala, Uganda. 5 The African Center of Excellence in Bioinformatics and Data-Intensive Sciences, The Infectious Diseases Institute, Makerere University, P.O. Box 22418, Kampala, Uganda. 6 Lira Regional Referral Hospital, P.O. Box 2, Lira, Uganda.

Received: 2 August 2021 Accepted: 14 April 2022
Published online: 12 May 2022

References
1. WHO_globalbcliststrb_2021–2025_backgrounddocument.pdf [Internet]. [cited 2021 Jul 23]. Available from: https://cdn.who.int/media/docs/default-source/docum ent.pdf?sfvrsn=68b854c2_9.
2. National strategic plan for tuberculosis and leprosy control 2020/21 – 2024/25 [Internet]. Ministry of Health | Government of Uganda. [cited 2021 Jul 23]. Available from: https://www.health.go.ug/cause-national-strategic-plan-for-tuberculosis-and-leprosy-control-2020-21-2024-25/.
3. Mithri G, Majivala RK, Kisaka S, Nyombi A, Mustini K, Kwegesa B, et al. Epidemiological profile of patients with rifampcin-resistant tuberculosis: an analysis of the Uganda National Tuberculosis Reference Laboratory Surveillance Data, 2014–2018. Antimicrob Resist Infect Control. 2021;10(1):76.
4. Singh R, Dwivedi SP, Ghanwar US, Meena R, Rajamani P, Prasad T. Recent updates on drug resistance in Mycobacterium tuberculosis. J Appl Microbiol. 2020;128(6):1547–67.
5. Guglielmetti L, Chiesi S, Eimer J, Dominguez J, Masini T, Vairane F, et al. Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician’s perspective. Future Microbiol. 2020;15:779–99.
6. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis [Internet]. [cited 2021 Jul 25]. Available from: https://www.who.int/publications-detail-direct/meet ing-report-of-the-who-expert-consultation-on-the-definition-of-extens ively-drug-resistant-tuberculosis.
7. Wasserman S, Louw G, Ramangopa L, Barber G, Hayes C, Omar SV, et al. Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa. J Antimicrob Chemother. 2019;74(8):2377–84.
8. Ismail N, Peters RH, Ismail NA, Omar SV. Clofazimine exposure in vitro selects efflux pump mutants and bedaquiline resistance. Antimicrob Agents Chemother. 2019;63(3):e02141-e2218.
9. Villellas C, Coeck N, Meehan CJ, Lounis N, de Jong B, Rigouts L, et al. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline. J Antimicrob Chemother. 2017;72(3):584–90.
10. Ghajavand H, Kargarpour Kamakoli M, Kanipour S, Pourazr Dizaji S, Masoumi M, Rahimi Jamnani F, et al. High prevalence of bedaquiline resistance in treatment-naïve tuberculosis patients and verapamil effectiveness. Antimicrob Agents Chemother. 2019;63(3):e02530-e02618.
11. Liu Y, Gao J, Du J, Shu W, Wang L, Wang Y, et al. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis. Int J Infect Dis. 2021;1(102):392–6.
12. Du J, Gao J, Yu Y, Li Q, Bai G, Shu W, et al. Low rate of acquired linezolid resistance in multidrug-resistant tuberculosis treated with bedaquiline-linezolid combination. Front Microbiol. 2021. https://doi.org/10.3389/fmicb.2021.65563/full.
13. Khawbung JL, Nath D, Chakraborty S. Drug resistant tuberculosis: a review. Comp Immunol Microbiol Infect Dis. 2021;1(74):101574.
14. Nimmo C, Millard J, van Dorp L, Brien K, Moodley S, Wolf A, et al. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis. Lancet Microbe. 2020;1(4):e165–74.
15. Organization WH. Global tuberculosis report 2018 [Internet]. World Health Organization; 2018 [cited 2021 Jul 25]. Available from: https://apps.who.int/iris/handle/10665/274453.
16. Kigozi E, Kasule GW, Musisi K, Lukoye D, Kyobbe S, Katabazi FA, et al. Prevalence and patterns of rifampicin and isoniazid resistance conferring mutations in Mycobacterium tuberculosis isolates from Uganda. PLoS ONE. 2018;13(5):e0198091.

17. nextera-xt-library-prep-reference-guide-15031942-05.pdf [Internet]. [cited 2021 Jul 25]. Available from: https://support.illumina.com/content/dam/illumina-support/documents/documentation/chemistry_documentation/sampleprepsexxt/nextera-xt/nextera-xt-library-prep-referencenote-15031942-05.pdf.

18. Babraham bioinformatics: FastQC a quality control tool for high throughput sequence data [Internet]. [cited 2021 Jul 25]. Available from: https://www.bioinformatics.babraham.ac.uk/projects/fastqc/.

19. MultiQ [Internet]. [cited 2021 Jul 25]. Available from: https://multiqc.info/.

20. Release TBProfiler v3.0.4 jodyphelan/TBProfiler [Internet]. GitHub. [cited 2021 Jul 25]. Available from: https://github.com/jodyphelan/TBProfiler/releases/tag/v3.0.4.

21. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754–60.

22. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. Bioinformatics. 2009;25(16):1778–9.

23. Garrison E, Marth G. Haplotype-based variant detection from short-read sequencing. 2012 Jul 20 [cited 2021 Jul 25]; Available from: http://arxiv.org/abs/1207.3907.

24. Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff. Fly. 2012;6(2):80–92.

25. Seemann T. tseemann/snippy [Internet]. 2021 [cited 2021 Jul 25]. Available from: https://github.com/tseemann/snippy.

26. Release Version 3.0.0 sanger-pathogens/gubbins [Internet]. GitHub. [cited 2021 Jul 25]. Available from: https://github.com/sanger-pathogens/gubbins/releases/tag/v3.0.0.

27. SNP-sites [Internet]. snp-sites. [cited 2021 Jul 25]. Available from: http://sanger-pathogens.github.io/snp-sites/.

28. Price MN, Dehal PS, Arkin AP. FastTree 2: Approximately maximum-likelihood trees for large alignments. PLoS ONE. 2010;5(3): e9490.

29. Letunic I, Bork P. Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees. Nucleic Acids Res. 2016;44(Web Server issue):W242–5.

30. Malinga LA. Characterization of efflux pumps genes involved in second-line drug resistance of tuberculosis. 178.

31. Tuberculosis [Internet]. [cited 2021 Jul 25]. Available from: https://www.theglobalfund.org/en/tuberculosis/.

32. TB Online: TB infections hit 90,000 a year in Uganda, overtake HIV rates [Internet]. [cited 2021 Jul 25]. Available from: https://www.tbonline.info/posts/2019/3/20/tb-infections-hit-90000-year-uganda-overtake-hiv-r/.

33. Alvarez N, Zapata E, Mejía GI, Realpe T, Araque P, Peláez C, et al. The structural modeling of the interaction between levofloxacin and the mycobacterium tuberculosis gyrase catalytic site sheds light on the mechanisms of fluoroquinolones resistant tuberculosis in Colombian clinical isolates. Biomed Res Int. 2014;2014(2014): e367268.

34. Morlock GP, Metchock B, Sikes D, Crawford JT, Cooksey RC, ethA, inhA, and katG loci of ethionamide-resistant clinical mycobacterium tuberculosis isolates. Antimicrob Agents Chemother. 2003;47(12):3799–805.

35. Xu L, Wang B, Hu M, Huo F, Guo S, Jing W, et al. Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2017;61(6):e00239-e317.

36. Zhang S, Chen J, Cui P, Shi W, Zhang W, Zhang Y. Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2015;70(9):2507–10.

37. Beckert P, Hilleman D, Kohl TA, Kalinowski J, Richter E, Niemann S, et al. rplC T460C identified as a dominant mutation in linezolid-resistant mycobacterium tuberculosis strains. Antimicrob Agents Chemother. 2012;56(5):2743–5.

38. NTLP: Uganda National guidelines for the programmatic management of drug-resistant tuberculosis, 2nd ed. 2016. 1–232.